Overview

Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer

Status:
Terminated

Trial end date:
2020-07-31

Target enrollment:

Participant gender:

Summary

This study will implement a new treatment regimen for patients with advanced and inoperable pancreatic cancer using chemotherapy combinations of Folfirinox or gemcitabine-nab paclitaxel (abraxane) followed by a short course of high dose radiation called Stereotactic Body Radiation Therapy (SBRT). While the chemotherapy is standard of care, the strategy of adding SBRT has not been investigated. An increase in the percentage of patients who can proceed to have surgery to remove their disease is anticipated with this approach.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Albumin-Bound Paclitaxel
Fluorouracil
Folfirinox
Folic Acid
Gemcitabine
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin
Paclitaxel